Product Description
Eptifibatide is a glycoprotein IIb/IIIa class platelet inhibitor drug used to reduce ischemic cardiac events in specific patient populations. Eptifibatide is an antiplatelet drug that reversibly binds and inhibits glycoprotein IIb/IIIa receptor of platelets. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK541066/)
Mechanisms of Action: GPIIb/IIIa Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Latvia | Lithuania | Luxembourg | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|